Short communication: High prevalence of drug-resistant human immunodeficiency virus type 1 in treatment-naïve patients in Greenland

AIDS Research and Human Retroviruses

Volumn 24, Issue 8, 2008, Pages 1073-1077

  Madsen, Tina Vasehus ^a   Lohse, Nicolai ^b   Jensen, Ea Stilling ^a   Obel, Niels ^c   Ladefoged, Karin ^d   Gerstoft, Jan ^c   Petersen, Ann Berith ^a   Nielsen, Claus ^a   Jørgensen, Louise Bruun ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c Mental Health Center Glostrup   (Denmark)

^d Dronning Ingrids Hospital   (Greenland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; EFAVIRENZ; LAMIVUDINE; NELFINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DENMARK; FEMALE; GENOTYPE; GREENLAND; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; MOLECULAR EPIDEMIOLOGY; MONOTHERAPY; PHYLOGENY; PRIORITY JOURNAL; STRUCTURAL GENE; VIRUS MUTATION; VIRUS TRANSMISSION;

COHORT STUDIES; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; GENES, POL; GREENLAND; HIV INFECTIONS; HIV-1; HUMANS; MALE; PHYLOGENY; PREVALENCE;

EID: 50249167691     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0049     Document Type: Article

References (24)

1. Peeters M: The genetic variability of HIV-1 and its implications. Transfus Clin Biol 2001;8:222-225.
2. Devereux H, Youle M, Johnson MA, Loveday C: Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999;13:123-127.
3. Cozzi-Lepri A, Sabin C, Staszewski S, et al.: Resistance profiles in patients with viral rebound on potent antiretroviral therapy. J Infect Dis 2000;181:1143-1147.
4. Quinn TC, Wawer MJ, Sewankankambo N, et al.: Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000;342:921-929.
5. Jørgensen LB, Christensen MB, Gerstoft J, et al.: Prevalence of drug resistance mutations and non-B subtypes in newly diagnosed HIV-1 patients in Denmark. Scand J Infect Dis 2003;35:800-807.
6. Wensing AMJ, van de Vijver DA, Angarano G, et al.: Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005;192:958-966.
7. Jørgensen LB, Gerstoft J, Mathiesen L, et al.: Low prevalence of transmitted HIV-1 drug resistance in newly diagnosed HIV-1 patients in Denmark from 2000-2004. Presented at: 4th European HIV Drug Resistance Workshop, 29-31 March 2006, Monte Carlo, Monaco. Abstract 22.
8. Lohse N, Ladefoged K, Pedersen L, et al.: Low effectiveness of highly active antiretroviral therapy and high mortality in the Greenland HIV-infected population. Scand J Infect Dis 2004;36:738-742.
9. Lohse N, Ladefoged K, Obel N: Implementation and effectiveness of antiretroviral therapy in Greenland. Emerg Infect Dis 2008;14:56-59.
10. Madsen TV, Leitner T, Lohse N, et al.: Introduction of HIV-1 into an isolated population: molecular epidemiologic study from Greenland. AIDS Res Hum Retroviruses 2007;23:675-681.
11. Lohse N, Hansen ABE, Jensen-Fangel S, et al.: Demographics of HIV-1 infection in Denmark: results from The Danish HIV Cohort Study. Scand J Infect Dis 2005;37:338-343.
12. Yerly S, Rakik A, De Loes SK, et al.: Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants. J Virol 1998;72:3520-3523.
13. Lindström A, Ohlis A, Huigen M, et al.: HIV-1 transmission cluster with M41L "singleton" mutation and decreased transmission of resistance in newly diagnosed Swedish homosexual men. Antivir Ther 2006;11:1031-1039.
14. Duwe S, Brunn M, Altmann D, et al.: Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naïve patients of the German seroconverter study. J Acquir Immune Defic Syndr 2001;26:266-273.
15. Brenner B, Wainberg M, Salomon H, et al.: Resistance to antiretroviral drugs in patients with primary HIV-1 infection. Int J Antimicrob Agents 2000;16:429-434.
16. Horban A, Stanczak JJ, Bakowska E, et al.: High prevalence of genotypic resistance to nucleoside reverse transcriptase inhibitors among therapy-naive individuals from the Warsaw cohort. Infection 2002;30:356-359.
17. Flandre P, Descamps D, Joly V, et al.: Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received. Antivir Ther 2003;8:65-72.
18. Marcelin A-G, Delaugerre C, Wirden M, et al.: Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J Med Virol 2004;72:162-165.
19. de Luca A, di Giambenedetto S, Romano L, et al.: Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapy. J Infect Dis 2006;193:1219-1222.
20. Cozzi-Lepri A, Ruiz L, Loveday C, et al.: Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their effect on virologic response the therapy. Presented at: 12th Conference on Retroviruses and Opportunistic Infections, 22-25 February 2005, Boston, Massachusetts. Abstract 708.
21. Brenner B, Routy J-P, Petrella M, et al.: Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 2002;76:1753-1761.
22. Tang JW, Pillay D: Transmission of HIV-1 drug resistance. J Clin Virol 2004;30:1-10.
23. Gandhi RT, Wurcel A, Rosenberg ES, et al.: Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis 2003;37:1693-1698.
24. Werdelin L, Misfeldt J, Melbye M, Olsen J: An update on knowledge and sexual behaviour among students in Greenland. Scand J Soc Med 1992;3:158-164.